Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

Abstract: This invention relates to a new method of activating 5? adenosine monophosphate-activated protein kinase (AMPK) to treat certain diseases and disorders using a salt of 4-chloro-N[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide in a dose-efficient manner. Diseases that may be treated in this way include type-2 diabetes.

Abstract: The invention relates to a compound of formula I, wherein: R1 is as defined in the specification, or a pharmaceutically acceptable salt or solvate thereof, which compounds are useful in the treatment treatment of a disorder or condition ameliorated by the activation of AMPK, particarly as prodrugs.

Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1, 2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of novel a transcriptional regulatory factor, referred to hereinafter as “Insulin Promoter Factor 1” or “Ipf1”.

Abstract: This invention provides an isolated nucleic acid molecule encoding a vhh-1 protein, an isolated protein which is a vhh-1 protein, vectors comprising an isolated nucleic acid molecule encoding a vhh-1 protein, mammalian cells comprising such vectors, antibodies directed to a vhh-1 protein, nucleic acid probes useful for detecting a nucleic acid molecule encoding a vhh-1 protein, pharmaceutical compositions related to the vhh-1 proteins, nonhuman transgenic animals which express a normal or a mutant vhh-1 protein. This invention further provides methods for inducing differentiation of floor plate cell, motor neuron, generating ventral neurons and treatments for alleviating abnormalities associated with the vhh-1 protein.

Abstract: This invention provides an isolated nucleic acid molecule encoding a vhh-1 protein, an isolated protein which is a vhh-1 protein, vectors comprising an isolated nucleic acid molecule encoding a vhh-1 protein, mamunalian cells comprising such vectors, antibodies directed to a vhh-1 protein, nucleic acid probes useful for detecting a nucleic acid molecule encoding a vhh-1 protein, pharmaceutical compositions related to the vhh-1 proteins, nonhuman transgenic animals which express a normal or a mutant vhh-1 protein. This invention further provides methods for inducing differentiation of floor plate cell, motor neuron, generating ventral neurons and treatments for alleviating abnormalities associated with the vhh-1 protein.

Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of novel a transcriptional regulatory factor, referred to hereinafter as “Insulin Promoter Factor 1” or “Ipf1”.

Abstract: This invention provides an isolated nucleic acid molecule encoding a vertebrate Vhh-1 protein. The preferred embodiments are rat and human Vhh-1 protein. This invention provides purified vertebrate Vhh-1 protein and a method to purify same. This invention provides isolated nucleic acid molecules encoding a human and a rat Vhh-1 protein and the purified rat and human Vhh-1 protein encoded by same. This invention provides a vector encoding a vertebrate Vhh-1 protein and mammalian cells comprising such vectors. This invention provides antibodies directed to a vertebrate Vhh-1 protein. This invention further provides nucleic acid probes useful for detecting a nucleic acid molecule encoding a vertebrate Vhh-1 protein. This invention provides pharmaceutical compounds comprising the human Vhh-1 protein. This invention provides nonhuman transgenic animals which express DNA encoding a vertebrate Vhh-1 protein.

Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of novel a transcriptional regulatory factor, referred to hereinafter as “Insulin Promoter Factor 1” or “Ipf1”.

Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of novel a transcriptional regulatory factor, referred to hereinafter as "Insulin Promoter Factor 1" or "Ipf1".

Abstract: A superoxide dismutase originally found in extracellular body fluids and therefore termed extracellular superoxide dismutase (EC-SOD) is prepared by growing a cell line, preferably of mammalian origin, producing EC-SOD and recovering the EC-SOD secreted from the cells or by inserting a DNA sequence encoding EC-SOD into a suitable vector, introducing the recombinant vector into a host cell, growing the cell and recovering the EC-SOD produced.EC-SOD may be used for the prophylaxis or treatment of diseases or disorders associated with the presence or formation of superoxide radicals.

Abstract: More effectively controlled expression of DNA sequences in coding desired heterologous proteins is achieved in differentiated eucaryotic cells by methods of this invention. Disclosed herein are control modules derived from selectively expressed genes of eucaryotic cells, such as, for example, insulin and chymotrypsin genes. These control elements contain cis-acting sequences which are responsive to indigenous trans-acting substances in the differentiated cell, which substances control the expression of the gene. Such cis-acting elements occur within the promoter region of such selectively expressed genes, and also in the five prime flanking region of the coding sequence in a position upstream of the promoter. These upstream enhancer sequences may be located using the methods disclosed herein, and ligated into differentiative expression modules for production of desired heterologous proteins.

Abstract: A superoxide dismutase originally found in extracellular body fluids and therefore termed extracellular superoxide dismutase (EC-SOD) is prepared by growing a cell line, preferably of mammalian origin, producing EC-SOD and recovering the EC-SOD secreted from the cells or by inserting a DNA sequence encoding EC-SOD into a suitable vector, introducing the recombinant vector into a host cell, growing the cell and recovering the EC-SOD produced.EC-SOD may be used for the prophylaxis or treatment of diseases or disorders associated with the presence or formation of superoxide radicals.

Abstract: Extracellular superoxide dismutase (EC-SOD) variants having the superoxide dismutating property of the native EC-SOD and having a modified (reduced or increased) binding to heparin as compared to recombinant EC-SOD C as well as compositions comprising such variants. The EC-SOD variants are polypeptides comprising: 1) amino acids 1-193 of native EC-SOD C and 2) an amino acid sequence which is based on, but different from amino acid moieties 194-222 of recombinant EC-SOD C, either by being truncated or prolonged at the C-terminal end or by having substituted or otherwise modified one or more amino acid moieties of the sequence. Another EC-SOD variant is one which differs from recombinant EC-SOD C by being a glycosylation-free mutant. The variants may be produced by recombinant DNA techniques and are useful in the treatment of various diseases.

Abstract: A superoxide dismutase originally found in extracellular body fluids and therefore termed extracellular superoxide dismutase (EC-SOD) is prepared by growing a cell line, preferably of mammalian origin, producing EC-SOD and recovering the EC-SOD secreted from the cells or by inserting a DNA sequence encoding EC-SOD into a suitable vector, introducing the recombinant vector into a host cell, growing the cell and recovering the EC-SOD produced.EC-SOD may be used for the prophylaxis or treatment of diseases or disorders associated with the presence or formation of superoxide radicals.

Abstract: A superoxide dismutase originally found in extracellular body fluids and therefore termed extracellular superoxide dismutase (EC-SOD) is prepared by growing a cell line, preferably of mammalian origin, producing EC-SOD and recovering the EC-SOD secreted from the cells or by inserting a DNA sequence encoding EC-SOD into a suitable vector, introducing the recombinant vector into a host cell, growing the cell and recovering the EC-SOD produced.EC-SOD may be used for the prophylaxis or treatment of diseases or disorders associated with the presence or formation of superoxide radicals.